Pre-Clinical Models of Infectious Diseases

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIAID

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N93027R00003

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN11

Additional Details
Set Aside

None

Place of Performance

UNITED STATES

SourceSAM
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS), has issued a presolicitation notice for the "Pre-Clinical Models of Infectious Diseases" program. This initiative is designed to advance research in microbiology and immunology, with the ultimate goal of developing vaccines, therapeutics, and diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The Division of Microbiology and Infectious Diseases (DMID) within NIAID is seeking to expand its existing Indefinite Delivery/Indefinite Quantity (IDIQ) contract program, which supports the development and refinement of animal and animal replacement models for infectious diseases. These models are critical for evaluating candidate medical countermeasures—such as vaccines, therapeutics, and diagnostics—against a wide array of infectious agents. The program also facilitates regulatory submissions, intellectual property applications, and provides essential data for extramural investigators and DHHS agency partners, supporting both emergency preparedness and biodefense priorities. The scope of this procurement encompasses four distinct task areas: - Task Area A: Small Animal Models of Infectious Diseases - Task Area B: Non-Human Primate Models of Infectious Diseases - Task Area C: Animal Replacement and Non-Traditional Animal Models of Infectious Diseases - Task Area D: Generation and Distribution of Specialized Reagents Offerors may submit proposals for one or more task areas, depending on their capabilities. The anticipated outcome is the award of multiple IDIQ base contracts, allowing successful offerors to join the existing contractor pools and compete for future task orders. The program is structured to provide rapid and effective responses to emerging infectious diseases and to support the product development pipeline from preclinical to clinical stages. Key requirements and deliverables include: - Development and refinement of animal and animal replacement models (including organ-on-a-chip technology, organoids, microphysiological systems, and artificial complex cell systems) for infectious disease research. - Evaluation of candidate countermeasures, including determination of maximum tolerated dose, minimum effective dose, safety, efficacy, pharmacokinetics, and pharmacodynamics. - Bridging studies between animal and animal replacement models. - Generation and distribution of specialized reagents, such as live life cycle stages for parasitic infections, live vectors, tissues for isolation of unculturable agents, and production of monoclonal and polyclonal antibodies. - Emphasis on pathogens of high public health importance, including RNA viruses with pandemic potential, antimicrobial-resistant bacteria, emerging infectious diseases, fungal diseases, neglected tropical diseases, and sexually transmitted infections. The program recognizes that a single organization may not possess all necessary expertise or facilities; therefore, consortia, partnerships, subcontracts, and consultants are permitted. However, contractors are responsible for all aspects of project management, including planning, implementation, communication, and oversight of subcontractors. The place of performance is within the United States, and the procurement is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology) and Product Service Code AN11. The contracting entity is the National Institutes of Health NIAID, a federal office within the Department of Health and Human Services. Interested offerors must submit proposals electronically via the NIAID Contract Proposal Submission (eCPS) website. A valid NIH electronic Research Administration (eRA) Commons account is required for submission, and registration may take up to four weeks. Proposals submitted by facsimile or email will not be accepted. The presolicitation notice is active, with a post date of October 19, 2026, and a response deadline of December 7, 2026. For further information, the primary contact is Ignacio Reyes ([email protected], 301-435-7574), and the secondary contact is Hamed Hassanzadeh Makou ([email protected], 301-761-7466). The solicitation and additional details can be accessed via SAM.gov at https://sam.gov/opp/48e64180d8534cc19ddbaf03306a366c/view. This opportunity is well-suited for organizations with expertise in preclinical infectious disease research, animal model development, biotechnology, and specialized reagent production. Contractors should be prepared to demonstrate their capabilities in one or more task areas and to manage complex, multi-faceted projects in collaboration with other entities as needed.